Loading...
Market
How many major partnerships will Monte Rosa sign by Oct 28, 2025?
2
Resolution / Starting Odds
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Monte Rosa Therapeutics official announcements or press releases
Story
Monte Rosa Therapeutics Announces $150M Global License Agreement with Novartis
Oct 28, 2024, 10:30 AM
Monte Rosa Therapeutics ($GLUE) has announced a global license agreement with Novartis ($NVS) to advance T and B Cell-modulating VAV1-directed molecular glue degraders. The deal includes $150 million upfront and potential payments up to $2.1 billion. This agreement aims to enhance Monte Rosa's capabilities in the field of targeted protein degradation, competing with companies like Kymera Therapeutics.
View original story
Similar markets
New partnership with a major pharma • 25%
Expansion of existing partnerships • 25%
No new partnership • 25%
Acquisition by another company • 25%
0-2 • 25%
3-5 • 25%
6-8 • 25%
More than 8 • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
Over $2 billion • 25%
No milestone payments • 25%
Up to $500 million • 25%
$500 million to $1 billion • 25%
Over $1 billion • 25%
0-2 • 25%
3-5 • 25%
6-8 • 25%
More than 8 • 25%
None • 25%
1-2 • 25%
3-4 • 25%
5 or more • 25%
0 • 25%
1 • 25%
2-3 • 25%
More than 3 • 25%
